| Schedule of Contract Assets and Contract Liabilities |
Total contract assets at June 30, 2024 were as follows:
|
|
|
|
|
(In thousands) |
|
Contract Assets |
|
Contract assets at December 31, 2023 |
|
$ |
706 |
|
Additions |
|
|
4,721 |
|
Transferred to receivables, net |
|
|
(1,935 |
) |
Contract assets at June 30, 2024 |
|
$ |
3,492 |
|
Total contract liabilities at June 30, 2024 were as follows:
|
|
|
|
|
(In thousands) |
|
Contract Liabilities |
|
Contract liabilities at December 31, 2023 |
|
$ |
4,775 |
|
Additions |
|
|
34 |
|
Amounts recognized into revenue |
|
|
(1,498 |
) |
Contract liabilities at June 30, 2024 |
|
$ |
3,311 |
|
|
| Schedule of Disaggregation of Revenues |
During the three and six months ended June 30, 2024 and 2023, the Company recorded product sales, net, as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
(In thousands) |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
VIVITROL |
|
$ |
111,873 |
|
|
$ |
102,071 |
|
|
$ |
209,532 |
|
|
$ |
198,730 |
|
ARISTADA and ARISTADA INITIO |
|
|
86,049 |
|
|
|
82,409 |
|
|
|
164,919 |
|
|
|
162,486 |
|
LYBALVI |
|
|
71,351 |
|
|
|
46,997 |
|
|
|
128,358 |
|
|
|
84,988 |
|
Total product sales, net |
|
$ |
269,273 |
|
|
$ |
231,477 |
|
|
$ |
502,809 |
|
|
$ |
446,204 |
|
|
| Schedule of Disaggregation of Revenues |
During the three and six months ended June 30, 2024 and 2023, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, 2024 |
|
|
Six Months Ended June 30, 2024 |
|
(In thousands) |
|
Manufacturing
Revenue |
|
|
Royalty
Revenue |
|
|
Total |
|
|
Manufacturing
Revenue |
|
|
Royalty
Revenue |
|
|
Total |
|
Long-acting INVEGA products(1) |
|
$ |
— |
|
|
$ |
78,739 |
|
|
$ |
78,739 |
|
|
$ |
— |
|
|
$ |
141,412 |
|
|
$ |
141,412 |
|
VUMERITY |
|
|
9,863 |
|
|
|
25,371 |
|
|
|
35,234 |
|
|
|
21,987 |
|
|
|
44,501 |
|
|
|
66,488 |
|
Other |
|
|
10,417 |
|
|
|
5,468 |
|
|
|
15,885 |
|
|
|
28,323 |
|
|
|
10,468 |
|
|
|
38,791 |
|
|
|
$ |
20,280 |
|
|
$ |
109,578 |
|
|
$ |
129,858 |
|
|
$ |
50,310 |
|
|
$ |
196,381 |
|
|
$ |
246,691 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, 2023 |
|
|
Six Months Ended June 30, 2023 |
|
(In thousands) |
|
Manufacturing
Revenue |
|
|
Royalty
Revenue |
|
|
Total |
|
|
Manufacturing
Revenue |
|
|
Royalty
Revenue |
|
|
Total |
|
Long-acting INVEGA products(1) |
|
$ |
— |
|
|
$ |
321,239 |
|
|
$ |
321,239 |
|
|
$ |
— |
|
|
$ |
334,801 |
|
|
$ |
334,801 |
|
VUMERITY |
|
|
10,369 |
|
|
|
21,926 |
|
|
|
32,295 |
|
|
|
23,018 |
|
|
|
38,151 |
|
|
|
61,169 |
|
Other |
|
|
21,529 |
|
|
|
10,850 |
|
|
|
32,379 |
|
|
|
47,320 |
|
|
|
15,485 |
|
|
|
62,805 |
|
|
|
$ |
31,898 |
|
|
$ |
354,015 |
|
|
$ |
385,913 |
|
|
$ |
70,338 |
|
|
$ |
388,437 |
|
|
$ |
458,775 |
|
(1)“long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).
|